Neuropathic Pain Database (NePDatabase)

Lawson Health Research Institute

Status: Completed

Conditions: Neuropathic Pain

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT00669006

13930E

R-07-835

Details and patient eligibility

About

To establish the infrastructure for a national neuropathic pain database.

To determine the longterm outcome of the management of chronic neuropathic pain including pain relief, disability, and quality of life.

Full description

The database will provide standard information on demographics, diagnosis, treatment interventions and outcome modeled on guidelines from the expert panel on initiatives on Methods, Measurement and Pain Assessment in Clinical Trials (IMMPACT)(Turk et al.,Pain 2003;106:337-345) The IMMPACT panel determined that patients should be evaluated according to six core domains as follows: Pain, physical functioning, emotional functioning, subject rating of global satisfaction with treatment, symptoms and adverse events and subject disposition.

The database will allow us to examine outcomes based on single (eg. pregabalin) and multiple (e.g tricyclic antidepressants and gabalin) therapeutic interventions. Standard guidelines for management of neuropathic pain acknowledge that polypharmacy is appropriate when individual first line treatments fail to provide adequate pain relief (Gilron I et al., CMAJ 2006; 175: 265-275; Attal N et al., European Journal of Neurology 2006; 13: 1153-1169)

Enrollment: 789 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Primarily Neuropathic Pain
• Able to give informed consent
• Estimated Life Expectancy of 2 years

Exclusion criteria

• Not primarily neuropathic pain
• Declined participation- too much traveling
• Declined participation- Unknown
• Declined participation- Other, specify
• Considered unreliable- personality disorder
• Considered unreliable- cognitive impairment
• Considered unreliable- substance abuse
• Considered unreliable- Other
• Language barrier
• Exceeded quarterly quota
• Presentation with progressive or recurrent cancer, fibromyalgia, perineal pain of unknown etiology
• Other, specify

Trial design

789 participants in 1 patient group

1

Description:

New patients with a diagnosis of Neuropathic Pain